Bleeding disorders: infectious agents pose new risks
A team of researchers has concluded that people with bleeding disorders such as hemophilia remain at risk from emerging infectious agents in plasma and blood transfusions.
For this reason, recombinant therapies, must always be an option.
Writing in the journal Lancet, Jamie Siegel, at Jefferson Medical College of Thomas Jefferson University in Philadelphia, Christopher A Ludlam, at the Royal Infirmary, Edinburgh, Scotland, UK, and colleagues say that coagulation-factor concentrates ( CFC ) from the blood plasma, used for individuals with bleeding disorders, are now deemed safe from most known infectious agents, such as hepatitis B and C viruses and HIV, in contrast to two decades ago.
But challenges from new agents mean plasma-derived products will continue to remain at risk.
The authors point out that an alternative recombinant products, which are made by expressing genes for clotting factors in the laboratory tissue culture dish lessen the likelihood of contamination by infectious agents.
"There will always be emerging pathogens and we won't always know what they are," says Siegel, who is director of the Hemophilia Center at Thomas Jefferson University Hospital. " We know that these pathogens may be in the blood supply, and if we have a population dependent on plasma derived products, they are always at risk."
She contends that infectious agents called prions, which are behind diseases such as new variant Creutzfeldt-Jakob disease ( Mad Cow disease ), may be the most worrisome of all because they are difficult to detect. She is concerned about them affecting mostly young children, and their effects decades later. " We don't know if we can get rid of prions," she says. " Currently, there is no available method to diagnose and deal with them effectively."
The continued debate about the safety of the blood supply and the use of blood-derived versus artificial products for those with bleeding disorders is under the constant threat of emerging infectious agents.
Blood-derived products work better in clotting blood, but carry the caveat of potential exposure to infectious agents in the blood supply. Recombinant clotting products made in the laboratory may not be quite as effective, but are virtually risk-free from contamination.
Up until now, decisions on using blood-derived versus recombinant blood products have been left to patients and physicians. Safety studies have not definitively made the case for either.
Siegel says that she is more confident in the safety of recombinant products with respect to infectious agents and doesn't want individuals with hemophilia to again be the victims of unsafe blood products as they were in the beginning of the AIDS epidemic in the early 1980s.
Source: Thomas Jefferson University, 2006
Hemophilia A: FDA has approved Adynovate, an antihemophilic factor PEGylated, for use in children and surgical settings
The FDA ( U.S. Food and Drug Administration ) has approved Adynovate [ antihemophilic factor ( recombinant), PEGylated ], an...
FDA has approved Idelvion, the first coagulation factor-albumin fusion protein to treat patients with hemophilia B
The FDA ( Food and Drug Administration ) has approved Idelvion, coagulation factor IX ( recombinant ), albumin fusion protein,...
Once-weekly prophylactic dosing in children: Alprolix meets primary endpoint and achieves low bleeding rates
Positive top-line results of the Kids B-LONG phase 3 clinical study that evaluated the safety, efficacy and pharmacokinetics of Alprolix...
Clopidogrel ( Plavix ) is a platelet aggregation inhibitor indicated for conditions such as myocardial infarction, stroke or established peripheral...
The FDA ( Food and Drug Administration ) has approved Eloctate, antihemophilic factor ( recombinant ), Fc fusion protein, for...
Hemophilia with inhibitors: a trial evaluating efficacy and safety of BAY 86-6150 has been discontinued
A trial evaluating the efficacy and safety of BAY 86-6150 in people with hemophilia A and hemophilia B with inhibitors...
Severe hemophilia B and AAV-mediated gene transfer: longer follow-up and expansion of the high dose cohort
Researchers have previously reported the preliminary safety and efficacy data of a novel gene transfer approach in six subjects with...
Severe hemophilia A: recombinant and plasma-derived Factor VIII products conferred similar risks of inhibitor development
For previously untreated children with severe hemophilia A, it is unclear whether the type of factor VIII product administered and...
Cancers in patients with hemophilia: a retrospective study from the Italian Association of Hemophilia Centers
The increased life expectancy of the hemophilia population, primarily as a result of advances in factor replacement therapy, has enabled...